Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Roux

Showing results (211-220 of 313) with videos related to

Pageof 32
Sort By:
Frontiers in Neuroscience|July 14, 2020
Ethanol-Induced Alterations in Placental and Fetal Cerebrocortical Annexin-A4 and Cerebral Cavernous Malformation Protein 3 Are Associated With Reductions in Fetal Cortical VEGF Receptor Binding and Microvascular DensityDaniel D Savage, Martina J Rosenberg, Laurent Coquet, et al.
Calcified Tissue International|August 6, 2013
Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosisChristian Roux, Neil Binkley, Steven Boonen, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 15, 2009
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapyDavid L Kendler, Christian Roux, Claude Laurent Benhamou, et al.
The Journal of Clinical Endocrinology and Metabolism|May 25, 2019
Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab TreatmentSerge Ferrari, Peter W Butler, David L Kendler, et al.
Bone|November 9, 2011
Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronatePhilip N Sambrook, Christian Roux, Jean-Pierre Devogelaer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 2, 2022
Barriers and Expectations for Patients in Post-Osteoporotic Fracture Care in France: The EFFEL StudyRobert Launois, Elise Cabout, Daniel Benamouzig, et al.
Studies in Health Technology and Informatics|September 12, 2009
Centralised versus decentralised management of patients' medical recordsCatherine Quantin, Gouenou Coatrieux, Maniane Fassa, et al.
Joint Bone Spine|September 25, 2012
Real frequency of ordinary and atypical sub-trochanteric and diaphyseal fractures in France based on X-rays and medical file analysisConstance Beaudouin-Bazire, Noémie Dalmas, Julie Bourgeois, et al.
The Journal of Clinical Endocrinology and Metabolism|October 17, 2023
Response to Letter to the Editor From Jagannath and Mayilvaganan: "FCH-PET/CT in Primary Hyperparathyroidism With Discordant/Negative MIBI Scintigraphy and Ultrasonography"Eugenie Koumakis, Mathieu Gauthé, Alessandro Martinino, et al.
The Journal of Clinical Endocrinology and Metabolism|February 7, 2023
FCH-PET/CT in Primary Hyperparathyroidism With Discordant/Negative MIBI Scintigraphy and UltrasonographyEugenie Koumakis, Mathieu Gauthé, Alessandro Martinino, et al.
Pageof 32

Showing results (211-220 of 313) with videos related to

Sort By:
Pageof 32
Frontiers in Neuroscience|July 14, 2020
Ethanol-Induced Alterations in Placental and Fetal Cerebrocortical Annexin-A4 and Cerebral Cavernous Malformation Protein 3 Are Associated With Reductions in Fetal Cortical VEGF Receptor Binding and Microvascular DensityDaniel D Savage, Martina J Rosenberg, Laurent Coquet, et al.
Calcified Tissue International|August 6, 2013
Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosisChristian Roux, Neil Binkley, Steven Boonen, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 15, 2009
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapyDavid L Kendler, Christian Roux, Claude Laurent Benhamou, et al.
The Journal of Clinical Endocrinology and Metabolism|May 25, 2019
Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab TreatmentSerge Ferrari, Peter W Butler, David L Kendler, et al.
Bone|November 9, 2011
Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronatePhilip N Sambrook, Christian Roux, Jean-Pierre Devogelaer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 2, 2022
Barriers and Expectations for Patients in Post-Osteoporotic Fracture Care in France: The EFFEL StudyRobert Launois, Elise Cabout, Daniel Benamouzig, et al.
Studies in Health Technology and Informatics|September 12, 2009
Centralised versus decentralised management of patients' medical recordsCatherine Quantin, Gouenou Coatrieux, Maniane Fassa, et al.
Joint Bone Spine|September 25, 2012
Real frequency of ordinary and atypical sub-trochanteric and diaphyseal fractures in France based on X-rays and medical file analysisConstance Beaudouin-Bazire, Noémie Dalmas, Julie Bourgeois, et al.
The Journal of Clinical Endocrinology and Metabolism|October 17, 2023
Response to Letter to the Editor From Jagannath and Mayilvaganan: "FCH-PET/CT in Primary Hyperparathyroidism With Discordant/Negative MIBI Scintigraphy and Ultrasonography"Eugenie Koumakis, Mathieu Gauthé, Alessandro Martinino, et al.
The Journal of Clinical Endocrinology and Metabolism|February 7, 2023
FCH-PET/CT in Primary Hyperparathyroidism With Discordant/Negative MIBI Scintigraphy and UltrasonographyEugenie Koumakis, Mathieu Gauthé, Alessandro Martinino, et al.
Pageof 32